nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB1—ovarian cancer	0.133	1	CbGaD
Ponatinib—ABCB11—Paclitaxel—ovarian cancer	0.0575	0.151	CbGbCtD
Ponatinib—ABCG2—Topotecan—ovarian cancer	0.0552	0.145	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—ovarian cancer	0.031	0.0815	CbGbCtD
Ponatinib—ABCG2—Paclitaxel—ovarian cancer	0.0273	0.0719	CbGbCtD
Ponatinib—ABCG2—Carboplatin—ovarian cancer	0.0257	0.0677	CbGbCtD
Ponatinib—ABCB1—Topotecan—ovarian cancer	0.0199	0.0524	CbGbCtD
Ponatinib—ABCG2—Docetaxel—ovarian cancer	0.0198	0.052	CbGbCtD
Ponatinib—CYP3A5—Paclitaxel—ovarian cancer	0.0151	0.0398	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—ovarian cancer	0.0147	0.0388	CbGbCtD
Ponatinib—CYP2C8—Paclitaxel—ovarian cancer	0.0146	0.0383	CbGbCtD
Ponatinib—ABCB1—Vinorelbine—ovarian cancer	0.014	0.0369	CbGbCtD
Ponatinib—CYP2D6—Vinorelbine—ovarian cancer	0.0132	0.0348	CbGbCtD
Ponatinib—CYP3A4—Topotecan—ovarian cancer	0.0119	0.0314	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—ovarian cancer	0.0109	0.0288	CbGbCtD
Ponatinib—ABCB1—Paclitaxel—ovarian cancer	0.00986	0.0259	CbGbCtD
Ponatinib—CYP3A4—Vinorelbine—ovarian cancer	0.00841	0.0221	CbGbCtD
Ponatinib—ABCB1—Docetaxel—ovarian cancer	0.00713	0.0187	CbGbCtD
Ponatinib—CYP3A4—Paclitaxel—ovarian cancer	0.00591	0.0155	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—ovarian cancer	0.00531	0.014	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—ovarian cancer	0.00501	0.0132	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—ovarian cancer	0.00427	0.0112	CbGbCtD
Ponatinib—CYP3A4—Doxorubicin—ovarian cancer	0.00318	0.00837	CbGbCtD
Ponatinib—FGFR4—embryo—ovarian cancer	0.0026	0.025	CbGeAlD
Ponatinib—FGFR4—Vinblastine—Vinorelbine—ovarian cancer	0.00209	0.545	CbGdCrCtD
Ponatinib—FGFR3—embryo—ovarian cancer	0.00177	0.017	CbGeAlD
Ponatinib—BCR—myometrium—ovarian cancer	0.00159	0.0153	CbGeAlD
Ponatinib—FGFR4—female reproductive system—ovarian cancer	0.00157	0.0151	CbGeAlD
Ponatinib—FGFR3—epithelium—ovarian cancer	0.00145	0.0139	CbGeAlD
Ponatinib—FGFR3—uterine cervix—ovarian cancer	0.00143	0.0138	CbGeAlD
Ponatinib—FGFR4—female gonad—ovarian cancer	0.00143	0.0138	CbGeAlD
Ponatinib—FGFR1—myometrium—ovarian cancer	0.00142	0.0136	CbGeAlD
Ponatinib—FGFR4—testis—ovarian cancer	0.00127	0.0122	CbGeAlD
Ponatinib—BCR—uterine cervix—ovarian cancer	0.00124	0.0119	CbGeAlD
Ponatinib—RET—embryo—ovarian cancer	0.00122	0.0117	CbGeAlD
Ponatinib—FGFR3—gonad—ovarian cancer	0.0012	0.0116	CbGeAlD
Ponatinib—BCR—decidua—ovarian cancer	0.00118	0.0114	CbGeAlD
Ponatinib—FGFR2—embryo—ovarian cancer	0.00116	0.0111	CbGeAlD
Ponatinib—BCR—endometrium—ovarian cancer	0.00112	0.0108	CbGeAlD
Ponatinib—TEK—embryo—ovarian cancer	0.00111	0.0107	CbGeAlD
Ponatinib—FGFR1—uterine cervix—ovarian cancer	0.0011	0.0106	CbGeAlD
Ponatinib—FGFR3—female reproductive system—ovarian cancer	0.00107	0.0103	CbGeAlD
Ponatinib—FGFR1—decidua—ovarian cancer	0.00105	0.0101	CbGeAlD
Ponatinib—BCR—gonad—ovarian cancer	0.00104	0.01	CbGeAlD
Ponatinib—BCR—uterus—ovarian cancer	0.00103	0.00993	CbGeAlD
Ponatinib—FLT3—gonad—ovarian cancer	0.00103	0.00993	CbGeAlD
Ponatinib—PDGFRA—embryo—ovarian cancer	0.00101	0.00968	CbGeAlD
Ponatinib—RET—epithelium—ovarian cancer	0.000996	0.00957	CbGeAlD
Ponatinib—SRC—embryo—ovarian cancer	0.000988	0.00949	CbGeAlD
Ponatinib—LCK—uterine cervix—ovarian cancer	0.000987	0.00949	CbGeAlD
Ponatinib—FGFR2—epithelium—ovarian cancer	0.000946	0.0091	CbGeAlD
Ponatinib—KDR—myometrium—ovarian cancer	0.000944	0.00908	CbGeAlD
Ponatinib—LCK—decidua—ovarian cancer	0.000941	0.00904	CbGeAlD
Ponatinib—RET—decidua—ovarian cancer	0.000941	0.00904	CbGeAlD
Ponatinib—FGFR2—uterine cervix—ovarian cancer	0.000938	0.00902	CbGeAlD
Ponatinib—BCR—female reproductive system—ovarian cancer	0.000929	0.00893	CbGeAlD
Ponatinib—FLT3—female reproductive system—ovarian cancer	0.000922	0.00887	CbGeAlD
Ponatinib—FGFR4—lymph node—ovarian cancer	0.00092	0.00885	CbGeAlD
Ponatinib—FGFR1—uterus—ovarian cancer	0.000919	0.00884	CbGeAlD
Ponatinib—KDR—embryo—ovarian cancer	0.000908	0.00873	CbGeAlD
Ponatinib—TEK—epithelium—ovarian cancer	0.000907	0.00872	CbGeAlD
Ponatinib—BCR—bone marrow—ovarian cancer	0.000877	0.00843	CbGeAlD
Ponatinib—FLT3—bone marrow—ovarian cancer	0.000871	0.00837	CbGeAlD
Ponatinib—FGFR3—testis—ovarian cancer	0.000866	0.00833	CbGeAlD
Ponatinib—TEK—decidua—ovarian cancer	0.000857	0.00824	CbGeAlD
Ponatinib—BCR—female gonad—ovarian cancer	0.000845	0.00813	CbGeAlD
Ponatinib—BCR—vagina—ovarian cancer	0.00084	0.00808	CbGeAlD
Ponatinib—FLT3—female gonad—ovarian cancer	0.000839	0.00807	CbGeAlD
Ponatinib—KIT—myometrium—ovarian cancer	0.000837	0.00805	CbGeAlD
Ponatinib—LCK—uterus—ovarian cancer	0.000823	0.00791	CbGeAlD
Ponatinib—TEK—endometrium—ovarian cancer	0.000813	0.00782	CbGeAlD
Ponatinib—SRC—epithelium—ovarian cancer	0.000806	0.00775	CbGeAlD
Ponatinib—KIT—embryo—ovarian cancer	0.000805	0.00774	CbGeAlD
Ponatinib—SRC—uterine cervix—ovarian cancer	0.000799	0.00768	CbGeAlD
Ponatinib—FGFR2—uterus—ovarian cancer	0.000782	0.00752	CbGeAlD
Ponatinib—PDGFRA—decidua—ovarian cancer	0.000776	0.00746	CbGeAlD
Ponatinib—SRC—decidua—ovarian cancer	0.000761	0.00732	CbGeAlD
Ponatinib—FGFR1—female gonad—ovarian cancer	0.000752	0.00723	CbGeAlD
Ponatinib—BCR—testis—ovarian cancer	0.00075	0.00721	CbGeAlD
Ponatinib—TEK—uterus—ovarian cancer	0.000749	0.00721	CbGeAlD
Ponatinib—FGFR1—vagina—ovarian cancer	0.000747	0.00719	CbGeAlD
Ponatinib—FLT3—testis—ovarian cancer	0.000744	0.00716	CbGeAlD
Ponatinib—KDR—epithelium—ovarian cancer	0.000741	0.00713	CbGeAlD
Ponatinib—KDR—uterine cervix—ovarian cancer	0.000735	0.00707	CbGeAlD
Ponatinib—ABL1—myometrium—ovarian cancer	0.000729	0.007	CbGeAlD
Ponatinib—FGFR2—female reproductive system—ovarian cancer	0.000703	0.00676	CbGeAlD
Ponatinib—ABL1—embryo—ovarian cancer	0.000701	0.00674	CbGeAlD
Ponatinib—KDR—decidua—ovarian cancer	0.0007	0.00673	CbGeAlD
Ponatinib—LCK—bone marrow—ovarian cancer	0.000698	0.00671	CbGeAlD
Ponatinib—PDGFRA—gonad—ovarian cancer	0.000683	0.00657	CbGeAlD
Ponatinib—PDGFRA—uterus—ovarian cancer	0.000679	0.00653	CbGeAlD
Ponatinib—TEK—female reproductive system—ovarian cancer	0.000674	0.00648	CbGeAlD
Ponatinib—LCK—female gonad—ovarian cancer	0.000673	0.00647	CbGeAlD
Ponatinib—SRC—gonad—ovarian cancer	0.00067	0.00644	CbGeAlD
Ponatinib—LCK—vagina—ovarian cancer	0.000669	0.00643	CbGeAlD
Ponatinib—FGFR1—testis—ovarian cancer	0.000667	0.00641	CbGeAlD
Ponatinib—KDR—endometrium—ovarian cancer	0.000665	0.00639	CbGeAlD
Ponatinib—KIT—epithelium—ovarian cancer	0.000657	0.00632	CbGeAlD
Ponatinib—KIT—uterine cervix—ovarian cancer	0.000651	0.00626	CbGeAlD
Ponatinib—FGFR2—female gonad—ovarian cancer	0.000639	0.00615	CbGeAlD
Ponatinib—KIT—decidua—ovarian cancer	0.000621	0.00597	CbGeAlD
Ponatinib—TEK—female gonad—ovarian cancer	0.000613	0.00589	CbGeAlD
Ponatinib—KDR—uterus—ovarian cancer	0.000613	0.00589	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—ovarian cancer	0.00061	0.00587	CbGeAlD
Ponatinib—SRC—female reproductive system—ovarian cancer	0.000599	0.00576	CbGeAlD
Ponatinib—RET—testis—ovarian cancer	0.000597	0.00574	CbGeAlD
Ponatinib—LCK—testis—ovarian cancer	0.000597	0.00574	CbGeAlD
Ponatinib—KIT—endometrium—ovarian cancer	0.000589	0.00566	CbGeAlD
Ponatinib—ABCB11—testis—ovarian cancer	0.000583	0.00561	CbGeAlD
Ponatinib—FGFR2—testis—ovarian cancer	0.000567	0.00545	CbGeAlD
Ponatinib—ABL1—uterine cervix—ovarian cancer	0.000567	0.00545	CbGeAlD
Ponatinib—PDGFRA—female gonad—ovarian cancer	0.000555	0.00534	CbGeAlD
Ponatinib—PDGFRA—vagina—ovarian cancer	0.000552	0.00531	CbGeAlD
Ponatinib—KDR—female reproductive system—ovarian cancer	0.000551	0.00529	CbGeAlD
Ponatinib—KIT—gonad—ovarian cancer	0.000546	0.00525	CbGeAlD
Ponatinib—SRC—female gonad—ovarian cancer	0.000545	0.00524	CbGeAlD
Ponatinib—TEK—testis—ovarian cancer	0.000544	0.00523	CbGeAlD
Ponatinib—BCR—lymph node—ovarian cancer	0.000543	0.00522	CbGeAlD
Ponatinib—KIT—uterus—ovarian cancer	0.000543	0.00522	CbGeAlD
Ponatinib—ABL1—decidua—ovarian cancer	0.00054	0.00519	CbGeAlD
Ponatinib—FLT3—lymph node—ovarian cancer	0.00054	0.00519	CbGeAlD
Ponatinib—KDR—bone marrow—ovarian cancer	0.00052	0.005	CbGeAlD
Ponatinib—ABL1—endometrium—ovarian cancer	0.000513	0.00493	CbGeAlD
Ponatinib—KDR—female gonad—ovarian cancer	0.000501	0.00482	CbGeAlD
Ponatinib—KDR—vagina—ovarian cancer	0.000498	0.00479	CbGeAlD
Ponatinib—PDGFRA—testis—ovarian cancer	0.000493	0.00474	CbGeAlD
Ponatinib—KIT—female reproductive system—ovarian cancer	0.000488	0.00469	CbGeAlD
Ponatinib—FGFR1—lymph node—ovarian cancer	0.000483	0.00465	CbGeAlD
Ponatinib—SRC—testis—ovarian cancer	0.000483	0.00464	CbGeAlD
Ponatinib—ABL1—gonad—ovarian cancer	0.000476	0.00457	CbGeAlD
Ponatinib—ABL1—uterus—ovarian cancer	0.000473	0.00454	CbGeAlD
Ponatinib—KIT—bone marrow—ovarian cancer	0.000461	0.00443	CbGeAlD
Ponatinib—ABCG2—myometrium—ovarian cancer	0.000459	0.00442	CbGeAlD
Ponatinib—KDR—testis—ovarian cancer	0.000444	0.00427	CbGeAlD
Ponatinib—KIT—female gonad—ovarian cancer	0.000444	0.00427	CbGeAlD
Ponatinib—KIT—vagina—ovarian cancer	0.000441	0.00424	CbGeAlD
Ponatinib—RET—lymph node—ovarian cancer	0.000433	0.00416	CbGeAlD
Ponatinib—LCK—lymph node—ovarian cancer	0.000433	0.00416	CbGeAlD
Ponatinib—ABL1—female reproductive system—ovarian cancer	0.000425	0.00408	CbGeAlD
Ponatinib—ABL1—bone marrow—ovarian cancer	0.000401	0.00386	CbGeAlD
Ponatinib—TEK—lymph node—ovarian cancer	0.000394	0.00379	CbGeAlD
Ponatinib—KIT—testis—ovarian cancer	0.000394	0.00379	CbGeAlD
Ponatinib—ABL1—female gonad—ovarian cancer	0.000387	0.00372	CbGeAlD
Ponatinib—ABL1—vagina—ovarian cancer	0.000384	0.00369	CbGeAlD
Ponatinib—ABCG2—uterine cervix—ovarian cancer	0.000358	0.00344	CbGeAlD
Ponatinib—PDGFRA—lymph node—ovarian cancer	0.000357	0.00343	CbGeAlD
Ponatinib—SRC—lymph node—ovarian cancer	0.00035	0.00337	CbGeAlD
Ponatinib—ABL1—testis—ovarian cancer	0.000343	0.0033	CbGeAlD
Ponatinib—ABCG2—decidua—ovarian cancer	0.000341	0.00328	CbGeAlD
Ponatinib—CYP2C8—endometrium—ovarian cancer	0.000333	0.0032	CbGeAlD
Ponatinib—CYP3A5—uterine cervix—ovarian cancer	0.000332	0.00319	CbGeAlD
Ponatinib—ABCG2—endometrium—ovarian cancer	0.000323	0.00311	CbGeAlD
Ponatinib—KDR—lymph node—ovarian cancer	0.000322	0.0031	CbGeAlD
Ponatinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000302	0.0788	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000302	0.0788	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000302	0.0788	CbGdCrCtD
Ponatinib—ABCG2—uterus—ovarian cancer	0.000298	0.00286	CbGeAlD
Ponatinib—KIT—lymph node—ovarian cancer	0.000285	0.00274	CbGeAlD
Ponatinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.00028	0.0729	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.00028	0.0729	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.00028	0.0729	CbGdCrCtD
Ponatinib—CYP2C8—female reproductive system—ovarian cancer	0.000276	0.00265	CbGeAlD
Ponatinib—ABCG2—bone marrow—ovarian cancer	0.000253	0.00243	CbGeAlD
Ponatinib—CYP2C8—vagina—ovarian cancer	0.000249	0.0024	CbGeAlD
Ponatinib—ABL1—lymph node—ovarian cancer	0.000249	0.00239	CbGeAlD
Ponatinib—ABCG2—female gonad—ovarian cancer	0.000244	0.00234	CbGeAlD
Ponatinib—ABCG2—vagina—ovarian cancer	0.000242	0.00233	CbGeAlD
Ponatinib—ABCB1—myometrium—ovarian cancer	0.000227	0.00218	CbGeAlD
Ponatinib—CYP3A5—female gonad—ovarian cancer	0.000226	0.00218	CbGeAlD
Ponatinib—CYP3A5—vagina—ovarian cancer	0.000225	0.00216	CbGeAlD
Ponatinib—CYP2C8—testis—ovarian cancer	0.000222	0.00214	CbGeAlD
Ponatinib—ABCB1—embryo—ovarian cancer	0.000218	0.0021	CbGeAlD
Ponatinib—Nilotinib—ABCB1—ovarian cancer	0.000216	0.545	CrCbGaD
Ponatinib—ABCG2—testis—ovarian cancer	0.000216	0.00208	CbGeAlD
Ponatinib—CYP3A4—female reproductive system—ovarian cancer	0.000187	0.00179	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—ovarian cancer	0.000184	0.00177	CbGeAlD
Ponatinib—Imatinib—ABCB1—ovarian cancer	0.00018	0.455	CrCbGaD
Ponatinib—ABCB1—epithelium—ovarian cancer	0.000178	0.00171	CbGeAlD
Ponatinib—ABCB1—uterine cervix—ovarian cancer	0.000176	0.0017	CbGeAlD
Ponatinib—ABCB1—decidua—ovarian cancer	0.000168	0.00161	CbGeAlD
Ponatinib—CYP2D6—female gonad—ovarian cancer	0.000167	0.00161	CbGeAlD
Ponatinib—ABCB1—endometrium—ovarian cancer	0.000159	0.00153	CbGeAlD
Ponatinib—ABCG2—lymph node—ovarian cancer	0.000157	0.00151	CbGeAlD
Ponatinib—CYP2D6—testis—ovarian cancer	0.000148	0.00142	CbGeAlD
Ponatinib—ABCB1—gonad—ovarian cancer	0.000148	0.00142	CbGeAlD
Ponatinib—ABCB1—uterus—ovarian cancer	0.000147	0.00141	CbGeAlD
Ponatinib—ABCB1—female reproductive system—ovarian cancer	0.000132	0.00127	CbGeAlD
Ponatinib—ABCB1—bone marrow—ovarian cancer	0.000125	0.0012	CbGeAlD
Ponatinib—ABCB1—female gonad—ovarian cancer	0.00012	0.00116	CbGeAlD
Ponatinib—ABCB1—vagina—ovarian cancer	0.000119	0.00115	CbGeAlD
Ponatinib—Chills—Docetaxel—ovarian cancer	0.000114	0.000667	CcSEcCtD
Ponatinib—Cough—Paclitaxel—ovarian cancer	0.000114	0.000666	CcSEcCtD
Ponatinib—Asthenia—Vinorelbine—ovarian cancer	0.000114	0.000664	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—ovarian cancer	0.000114	0.000664	CcSEcCtD
Ponatinib—Arrhythmia—Docetaxel—ovarian cancer	0.000114	0.000664	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—ovarian cancer	0.000113	0.00066	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—ovarian cancer	0.000113	0.000659	CcSEcCtD
Ponatinib—Hypertension—Paclitaxel—ovarian cancer	0.000113	0.000659	CcSEcCtD
Ponatinib—Alopecia—Docetaxel—ovarian cancer	0.000112	0.000657	CcSEcCtD
Ponatinib—Pruritus—Vinorelbine—ovarian cancer	0.000112	0.000655	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—ovarian cancer	0.000112	0.000655	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000112	0.000652	CcSEcCtD
Ponatinib—Mental disorder—Docetaxel—ovarian cancer	0.000112	0.000651	CcSEcCtD
Ponatinib—Myalgia—Paclitaxel—ovarian cancer	0.000111	0.00065	CcSEcCtD
Ponatinib—Arthralgia—Paclitaxel—ovarian cancer	0.000111	0.00065	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000111	0.000648	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—ovarian cancer	0.000111	0.000647	CcSEcCtD
Ponatinib—Erythema—Docetaxel—ovarian cancer	0.000111	0.000647	CcSEcCtD
Ponatinib—Malnutrition—Docetaxel—ovarian cancer	0.000111	0.000647	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000111	0.000645	CcSEcCtD
Ponatinib—Nausea—Topotecan—ovarian cancer	0.00011	0.000643	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000109	0.000639	CcSEcCtD
Ponatinib—Dry mouth—Paclitaxel—ovarian cancer	0.000109	0.000635	CcSEcCtD
Ponatinib—Diarrhoea—Vinorelbine—ovarian cancer	0.000109	0.000634	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—ovarian cancer	0.000108	0.00063	CcSEcCtD
Ponatinib—Nausea—Melphalan—ovarian cancer	0.000108	0.00063	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000108	0.000628	CcSEcCtD
Ponatinib—Back pain—Docetaxel—ovarian cancer	0.000107	0.000626	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—ovarian cancer	0.000107	0.000623	CcSEcCtD
Ponatinib—Oedema—Paclitaxel—ovarian cancer	0.000107	0.000623	CcSEcCtD
Ponatinib—ABCB1—testis—ovarian cancer	0.000107	0.00102	CbGeAlD
Ponatinib—Muscle spasms—Docetaxel—ovarian cancer	0.000107	0.000622	CcSEcCtD
Ponatinib—Infection—Paclitaxel—ovarian cancer	0.000106	0.000619	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—ovarian cancer	0.000105	0.000615	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—ovarian cancer	0.000105	0.000614	CcSEcCtD
Ponatinib—Dizziness—Vinorelbine—ovarian cancer	0.000105	0.000612	CcSEcCtD
Ponatinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000105	0.000611	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000105	0.00061	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—ovarian cancer	0.000105	0.00061	CcSEcCtD
Ponatinib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000104	0.00061	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—ovarian cancer	0.000104	0.000606	CcSEcCtD
Ponatinib—Skin disorder—Paclitaxel—ovarian cancer	0.000104	0.000605	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000103	0.000604	CcSEcCtD
Ponatinib—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000103	0.000602	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000103	0.0006	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—ovarian cancer	0.000102	0.000598	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—ovarian cancer	0.000102	0.000595	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000101	0.000591	CcSEcCtD
Ponatinib—Vomiting—Vinorelbine—ovarian cancer	0.000101	0.000589	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—ovarian cancer	0.0001	0.000586	CcSEcCtD
Ponatinib—Rash—Vinorelbine—ovarian cancer	0.0001	0.000584	CcSEcCtD
Ponatinib—Dermatitis—Vinorelbine—ovarian cancer	9.99e-05	0.000583	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—ovarian cancer	9.99e-05	0.000583	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—ovarian cancer	9.97e-05	0.000582	CcSEcCtD
Ponatinib—Headache—Vinorelbine—ovarian cancer	9.94e-05	0.00058	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—ovarian cancer	9.92e-05	0.000579	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—ovarian cancer	9.73e-05	0.000568	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	9.72e-05	0.000568	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—ovarian cancer	9.71e-05	0.000567	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—ovarian cancer	9.68e-05	0.000565	CcSEcCtD
Ponatinib—Cough—Docetaxel—ovarian cancer	9.67e-05	0.000565	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—ovarian cancer	9.67e-05	0.000564	CcSEcCtD
Ponatinib—Insomnia—Paclitaxel—ovarian cancer	9.65e-05	0.000563	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—ovarian cancer	9.62e-05	0.000562	CcSEcCtD
Ponatinib—Paraesthesia—Paclitaxel—ovarian cancer	9.58e-05	0.000559	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—ovarian cancer	9.57e-05	0.000559	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—ovarian cancer	9.57e-05	0.000558	CcSEcCtD
Ponatinib—Infestation—Epirubicin—ovarian cancer	9.57e-05	0.000558	CcSEcCtD
Ponatinib—Dyspnoea—Paclitaxel—ovarian cancer	9.51e-05	0.000555	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—ovarian cancer	9.43e-05	0.000551	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—ovarian cancer	9.43e-05	0.000551	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—ovarian cancer	9.43e-05	0.00055	CcSEcCtD
Ponatinib—Nausea—Vinorelbine—ovarian cancer	9.42e-05	0.00055	CcSEcCtD
Ponatinib—Dyspepsia—Paclitaxel—ovarian cancer	9.39e-05	0.000548	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—ovarian cancer	9.38e-05	0.000547	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	9.37e-05	0.000547	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—ovarian cancer	9.32e-05	0.000544	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—ovarian cancer	9.32e-05	0.000544	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—ovarian cancer	9.3e-05	0.000543	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—ovarian cancer	9.28e-05	0.000542	CcSEcCtD
Ponatinib—Decreased appetite—Paclitaxel—ovarian cancer	9.28e-05	0.000541	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—ovarian cancer	9.23e-05	0.000539	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	9.23e-05	0.000539	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	9.21e-05	0.000538	CcSEcCtD
Ponatinib—Fatigue—Paclitaxel—ovarian cancer	9.2e-05	0.000537	CcSEcCtD
Ponatinib—Constipation—Paclitaxel—ovarian cancer	9.13e-05	0.000533	CcSEcCtD
Ponatinib—Pain—Paclitaxel—ovarian cancer	9.13e-05	0.000533	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—ovarian cancer	9.05e-05	0.000528	CcSEcCtD
Ponatinib—Oedema—Docetaxel—ovarian cancer	9.04e-05	0.000528	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—ovarian cancer	9.02e-05	0.000527	CcSEcCtD
Ponatinib—Infection—Docetaxel—ovarian cancer	8.99e-05	0.000525	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—ovarian cancer	8.98e-05	0.000524	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—ovarian cancer	8.95e-05	0.000523	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—ovarian cancer	8.9e-05	0.00052	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—ovarian cancer	8.87e-05	0.000518	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—ovarian cancer	8.86e-05	0.000517	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—ovarian cancer	8.85e-05	0.000517	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—ovarian cancer	8.85e-05	0.000517	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—ovarian cancer	8.79e-05	0.000513	CcSEcCtD
Ponatinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.73e-05	0.000509	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.68e-05	0.000506	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—ovarian cancer	8.63e-05	0.000504	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—ovarian cancer	8.63e-05	0.000504	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—ovarian cancer	8.63e-05	0.000504	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—ovarian cancer	8.6e-05	0.000502	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—ovarian cancer	8.59e-05	0.000501	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—ovarian cancer	8.54e-05	0.000499	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—ovarian cancer	8.46e-05	0.000494	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—ovarian cancer	8.44e-05	0.000493	CcSEcCtD
Ponatinib—Abdominal pain—Paclitaxel—ovarian cancer	8.44e-05	0.000492	CcSEcCtD
Ponatinib—Body temperature increased—Paclitaxel—ovarian cancer	8.44e-05	0.000492	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	8.37e-05	0.000489	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—ovarian cancer	8.35e-05	0.000487	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—ovarian cancer	8.28e-05	0.000483	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.24e-05	0.000481	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—ovarian cancer	8.18e-05	0.000478	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—ovarian cancer	8.12e-05	0.000474	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—ovarian cancer	8.06e-05	0.000471	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—ovarian cancer	8.02e-05	0.000468	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—ovarian cancer	7.99e-05	0.000466	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—ovarian cancer	7.97e-05	0.000465	CcSEcCtD
Ponatinib—Flushing—Epirubicin—ovarian cancer	7.97e-05	0.000465	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—ovarian cancer	7.96e-05	0.000465	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—ovarian cancer	7.95e-05	0.000464	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—ovarian cancer	7.91e-05	0.000461	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—ovarian cancer	7.86e-05	0.000459	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—ovarian cancer	7.83e-05	0.000457	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.81e-05	0.000456	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—ovarian cancer	7.81e-05	0.000456	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—ovarian cancer	7.8e-05	0.000455	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—ovarian cancer	7.79e-05	0.000455	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—ovarian cancer	7.74e-05	0.000452	CcSEcCtD
Ponatinib—Pain—Docetaxel—ovarian cancer	7.73e-05	0.000451	CcSEcCtD
Ponatinib—Constipation—Docetaxel—ovarian cancer	7.73e-05	0.000451	CcSEcCtD
Ponatinib—ABCB1—lymph node—ovarian cancer	7.73e-05	0.000743	CbGeAlD
Ponatinib—Chills—Epirubicin—ovarian cancer	7.7e-05	0.00045	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—ovarian cancer	7.67e-05	0.000448	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—ovarian cancer	7.66e-05	0.000447	CcSEcCtD
Ponatinib—Asthenia—Paclitaxel—ovarian cancer	7.66e-05	0.000447	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—ovarian cancer	7.59e-05	0.000443	CcSEcCtD
Ponatinib—Pruritus—Paclitaxel—ovarian cancer	7.55e-05	0.000441	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—ovarian cancer	7.52e-05	0.000439	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—ovarian cancer	7.47e-05	0.000436	CcSEcCtD
Ponatinib—Erythema—Epirubicin—ovarian cancer	7.47e-05	0.000436	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—ovarian cancer	7.43e-05	0.000433	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—ovarian cancer	7.4e-05	0.000432	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—ovarian cancer	7.37e-05	0.00043	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—ovarian cancer	7.37e-05	0.00043	CcSEcCtD
Ponatinib—Diarrhoea—Paclitaxel—ovarian cancer	7.3e-05	0.000426	CcSEcCtD
Ponatinib—Back pain—Epirubicin—ovarian cancer	7.23e-05	0.000422	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—ovarian cancer	7.21e-05	0.000421	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—ovarian cancer	7.19e-05	0.00042	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—ovarian cancer	7.16e-05	0.000418	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—ovarian cancer	7.15e-05	0.000417	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—ovarian cancer	7.15e-05	0.000417	CcSEcCtD
Ponatinib—Chills—Doxorubicin—ovarian cancer	7.13e-05	0.000416	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—ovarian cancer	7.1e-05	0.000414	CcSEcCtD
Ponatinib—Dizziness—Paclitaxel—ovarian cancer	7.06e-05	0.000412	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—ovarian cancer	7.04e-05	0.000411	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—ovarian cancer	7.02e-05	0.00041	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—ovarian cancer	6.96e-05	0.000406	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—ovarian cancer	6.92e-05	0.000404	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—ovarian cancer	6.92e-05	0.000404	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—ovarian cancer	6.91e-05	0.000403	CcSEcCtD
Ponatinib—Vomiting—Paclitaxel—ovarian cancer	6.78e-05	0.000396	CcSEcCtD
Ponatinib—Rash—Paclitaxel—ovarian cancer	6.73e-05	0.000393	CcSEcCtD
Ponatinib—Dermatitis—Paclitaxel—ovarian cancer	6.72e-05	0.000392	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—ovarian cancer	6.69e-05	0.000391	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—ovarian cancer	6.69e-05	0.000391	CcSEcCtD
Ponatinib—Headache—Paclitaxel—ovarian cancer	6.68e-05	0.00039	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—ovarian cancer	6.65e-05	0.000388	CcSEcCtD
Ponatinib—Cough—Epirubicin—ovarian cancer	6.52e-05	0.000381	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—ovarian cancer	6.52e-05	0.00038	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—ovarian cancer	6.49e-05	0.000379	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—ovarian cancer	6.45e-05	0.000377	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—ovarian cancer	6.4e-05	0.000374	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—ovarian cancer	6.39e-05	0.000373	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—ovarian cancer	6.36e-05	0.000371	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—ovarian cancer	6.36e-05	0.000371	CcSEcCtD
Ponatinib—Nausea—Paclitaxel—ovarian cancer	6.34e-05	0.00037	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.32e-05	0.000369	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—ovarian cancer	6.22e-05	0.000363	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—ovarian cancer	6.19e-05	0.000361	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—ovarian cancer	6.19e-05	0.000361	CcSEcCtD
Ponatinib—Oedema—Epirubicin—ovarian cancer	6.1e-05	0.000356	CcSEcCtD
Ponatinib—Infection—Epirubicin—ovarian cancer	6.06e-05	0.000354	CcSEcCtD
Ponatinib—Cough—Doxorubicin—ovarian cancer	6.04e-05	0.000352	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—ovarian cancer	5.98e-05	0.000349	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—ovarian cancer	5.98e-05	0.000349	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—ovarian cancer	5.97e-05	0.000349	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—ovarian cancer	5.97e-05	0.000349	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—ovarian cancer	5.93e-05	0.000346	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—ovarian cancer	5.9e-05	0.000344	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—ovarian cancer	5.89e-05	0.000344	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—ovarian cancer	5.89e-05	0.000344	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.85e-05	0.000341	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—ovarian cancer	5.76e-05	0.000336	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—ovarian cancer	5.75e-05	0.000336	CcSEcCtD
Ponatinib—Rash—Docetaxel—ovarian cancer	5.7e-05	0.000333	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—ovarian cancer	5.7e-05	0.000333	CcSEcCtD
Ponatinib—Headache—Docetaxel—ovarian cancer	5.67e-05	0.000331	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—ovarian cancer	5.64e-05	0.00033	CcSEcCtD
Ponatinib—Infection—Doxorubicin—ovarian cancer	5.61e-05	0.000327	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.56e-05	0.000324	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—ovarian cancer	5.54e-05	0.000323	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—ovarian cancer	5.53e-05	0.000323	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—ovarian cancer	5.52e-05	0.000322	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—ovarian cancer	5.48e-05	0.00032	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—ovarian cancer	5.48e-05	0.00032	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—ovarian cancer	5.46e-05	0.000319	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—ovarian cancer	5.44e-05	0.000317	CcSEcCtD
Ponatinib—Nausea—Docetaxel—ovarian cancer	5.37e-05	0.000314	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—ovarian cancer	5.37e-05	0.000313	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—ovarian cancer	5.3e-05	0.00031	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.27e-05	0.000307	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—ovarian cancer	5.26e-05	0.000307	CcSEcCtD
Ponatinib—Pain—Epirubicin—ovarian cancer	5.22e-05	0.000305	CcSEcCtD
Ponatinib—Constipation—Epirubicin—ovarian cancer	5.22e-05	0.000305	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.14e-05	0.0003	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—ovarian cancer	5.11e-05	0.000298	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—ovarian cancer	5.07e-05	0.000296	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—ovarian cancer	5.03e-05	0.000294	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.99e-05	0.000291	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—ovarian cancer	4.97e-05	0.00029	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—ovarian cancer	4.91e-05	0.000286	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.87e-05	0.000284	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—ovarian cancer	4.87e-05	0.000284	CcSEcCtD
Ponatinib—Pain—Doxorubicin—ovarian cancer	4.83e-05	0.000282	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—ovarian cancer	4.83e-05	0.000282	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—ovarian cancer	4.82e-05	0.000282	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—ovarian cancer	4.82e-05	0.000282	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.62e-05	0.000269	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—ovarian cancer	4.46e-05	0.00026	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—ovarian cancer	4.46e-05	0.00026	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—ovarian cancer	4.38e-05	0.000256	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—ovarian cancer	4.32e-05	0.000252	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—ovarian cancer	4.17e-05	0.000244	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—ovarian cancer	4.05e-05	0.000236	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—ovarian cancer	4.03e-05	0.000235	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—ovarian cancer	3.99e-05	0.000233	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—ovarian cancer	3.88e-05	0.000226	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—ovarian cancer	3.86e-05	0.000225	CcSEcCtD
Ponatinib—Rash—Epirubicin—ovarian cancer	3.85e-05	0.000225	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—ovarian cancer	3.84e-05	0.000224	CcSEcCtD
Ponatinib—Headache—Epirubicin—ovarian cancer	3.82e-05	0.000223	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—ovarian cancer	3.73e-05	0.000218	CcSEcCtD
Ponatinib—Nausea—Epirubicin—ovarian cancer	3.62e-05	0.000212	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—ovarian cancer	3.59e-05	0.00021	CcSEcCtD
Ponatinib—Rash—Doxorubicin—ovarian cancer	3.56e-05	0.000208	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—ovarian cancer	3.56e-05	0.000208	CcSEcCtD
Ponatinib—Headache—Doxorubicin—ovarian cancer	3.54e-05	0.000206	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—ovarian cancer	3.35e-05	0.000196	CcSEcCtD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—ovarian cancer	2.43e-06	1.17e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.43e-06	1.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—ovarian cancer	2.42e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—ovarian cancer	2.42e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—ovarian cancer	2.42e-06	1.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—ovarian cancer	2.42e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—ovarian cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—ovarian cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—ovarian cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	2.4e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—ovarian cancer	2.4e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—ovarian cancer	2.4e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—ovarian cancer	2.4e-06	1.16e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—ovarian cancer	2.4e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—ovarian cancer	2.4e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.39e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK3—ovarian cancer	2.39e-06	1.15e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—ovarian cancer	2.39e-06	1.15e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—ovarian cancer	2.36e-06	1.14e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—ovarian cancer	2.36e-06	1.14e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—ovarian cancer	2.36e-06	1.14e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—ovarian cancer	2.36e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—ovarian cancer	2.35e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—ovarian cancer	2.35e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—ovarian cancer	2.35e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—ovarian cancer	2.35e-06	1.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—ovarian cancer	2.34e-06	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—ovarian cancer	2.33e-06	1.12e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—ovarian cancer	2.33e-06	1.12e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—ovarian cancer	2.33e-06	1.12e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—ovarian cancer	2.31e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—ovarian cancer	2.31e-06	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	1.11e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—ovarian cancer	2.29e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—ovarian cancer	2.29e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—ovarian cancer	2.28e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—ovarian cancer	2.28e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.27e-06	1.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—ovarian cancer	2.27e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—ovarian cancer	2.27e-06	1.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	2.26e-06	1.09e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—ovarian cancer	2.26e-06	1.09e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—ovarian cancer	2.26e-06	1.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—ovarian cancer	2.24e-06	1.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—ovarian cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—ovarian cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—ovarian cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—ovarian cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—ovarian cancer	2.22e-06	1.07e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—ovarian cancer	2.22e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—ovarian cancer	2.22e-06	1.07e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—ovarian cancer	2.22e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—ovarian cancer	2.21e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—ovarian cancer	2.21e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—ovarian cancer	2.21e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—ovarian cancer	2.2e-06	1.06e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—ovarian cancer	2.2e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—ovarian cancer	2.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—ovarian cancer	2.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—ovarian cancer	2.18e-06	1.05e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—ovarian cancer	2.16e-06	1.04e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—ovarian cancer	2.15e-06	1.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—ovarian cancer	2.15e-06	1.03e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—ovarian cancer	2.15e-06	1.03e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—ovarian cancer	2.15e-06	1.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—ovarian cancer	2.14e-06	1.03e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	2.14e-06	1.03e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—ovarian cancer	2.13e-06	1.03e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—ovarian cancer	2.13e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—ovarian cancer	2.13e-06	1.02e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—ovarian cancer	2.12e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	2.12e-06	1.02e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—ovarian cancer	2.12e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—ovarian cancer	2.1e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—ovarian cancer	2.1e-06	1.01e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—ovarian cancer	2.1e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—ovarian cancer	2.09e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	2.09e-06	1.01e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—ovarian cancer	2.09e-06	1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	2.08e-06	1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—ovarian cancer	2.07e-06	9.95e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—ovarian cancer	2.07e-06	9.94e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.06e-06	9.92e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—ovarian cancer	2.06e-06	9.92e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—ovarian cancer	2.05e-06	9.85e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—ovarian cancer	2.04e-06	9.82e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—ovarian cancer	2.04e-06	9.82e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—ovarian cancer	2.04e-06	9.82e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	2.03e-06	9.8e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	2.03e-06	9.79e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—ovarian cancer	2.03e-06	9.77e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—ovarian cancer	2.01e-06	9.7e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—ovarian cancer	2.01e-06	9.7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	2.01e-06	9.69e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.99e-06	9.6e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—ovarian cancer	1.99e-06	9.6e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—ovarian cancer	1.98e-06	9.55e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—ovarian cancer	1.97e-06	9.5e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—ovarian cancer	1.97e-06	9.5e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—ovarian cancer	1.97e-06	9.48e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—ovarian cancer	1.97e-06	9.47e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	1.97e-06	9.46e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—ovarian cancer	1.97e-06	9.46e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.97e-06	9.46e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—ovarian cancer	1.96e-06	9.43e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—ovarian cancer	1.95e-06	9.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FASN—ovarian cancer	1.95e-06	9.39e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—ovarian cancer	1.93e-06	9.28e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—ovarian cancer	1.93e-06	9.27e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—ovarian cancer	1.92e-06	9.26e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	1.92e-06	9.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.92e-06	9.24e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—ovarian cancer	1.9e-06	9.16e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—ovarian cancer	1.9e-06	9.15e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	9.14e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—ovarian cancer	1.89e-06	9.08e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.88e-06	9.05e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—ovarian cancer	1.88e-06	9.04e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—ovarian cancer	1.87e-06	9.03e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	1.87e-06	8.98e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—ovarian cancer	1.86e-06	8.95e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—ovarian cancer	1.86e-06	8.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	1.86e-06	8.94e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—ovarian cancer	1.85e-06	8.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—ovarian cancer	1.85e-06	8.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.85e-06	8.92e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—ovarian cancer	1.84e-06	8.84e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—ovarian cancer	1.83e-06	8.83e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—ovarian cancer	1.83e-06	8.8e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—ovarian cancer	1.83e-06	8.79e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—ovarian cancer	1.82e-06	8.78e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—ovarian cancer	1.82e-06	8.76e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—ovarian cancer	1.81e-06	8.71e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—ovarian cancer	1.8e-06	8.69e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—ovarian cancer	1.79e-06	8.64e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—ovarian cancer	1.79e-06	8.64e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—ovarian cancer	1.78e-06	8.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.78e-06	8.55e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.77e-06	8.53e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—ovarian cancer	1.77e-06	8.52e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	1.77e-06	8.5e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—ovarian cancer	1.76e-06	8.46e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—ovarian cancer	1.76e-06	8.46e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—ovarian cancer	1.75e-06	8.42e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—ovarian cancer	1.75e-06	8.41e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—ovarian cancer	1.74e-06	8.38e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.74e-06	8.37e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.73e-06	8.32e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—ovarian cancer	1.73e-06	8.31e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—ovarian cancer	1.71e-06	8.24e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.71e-06	8.24e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	1.71e-06	8.22e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—ovarian cancer	1.71e-06	8.21e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—ovarian cancer	1.7e-06	8.2e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—ovarian cancer	1.7e-06	8.16e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—ovarian cancer	1.69e-06	8.12e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—ovarian cancer	1.68e-06	8.1e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—ovarian cancer	1.66e-06	7.99e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—ovarian cancer	1.65e-06	7.95e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—ovarian cancer	1.64e-06	7.91e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—ovarian cancer	1.64e-06	7.88e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	1.63e-06	7.87e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	1.63e-06	7.86e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—ovarian cancer	1.62e-06	7.79e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—ovarian cancer	1.62e-06	7.78e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—ovarian cancer	1.61e-06	7.77e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—ovarian cancer	1.61e-06	7.77e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—ovarian cancer	1.61e-06	7.77e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.61e-06	7.77e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—ovarian cancer	1.61e-06	7.76e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—ovarian cancer	1.61e-06	7.76e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—ovarian cancer	1.6e-06	7.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.58e-06	7.59e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—ovarian cancer	1.57e-06	7.55e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	1.56e-06	7.53e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	1.56e-06	7.5e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	7.47e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—ovarian cancer	1.55e-06	7.45e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	1.55e-06	7.44e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—ovarian cancer	1.52e-06	7.34e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—ovarian cancer	1.51e-06	7.25e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.51e-06	7.25e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.5e-06	7.24e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—ovarian cancer	1.5e-06	7.24e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—ovarian cancer	1.5e-06	7.23e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—ovarian cancer	1.49e-06	7.19e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—ovarian cancer	1.49e-06	7.17e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.48e-06	7.12e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	1.47e-06	7.08e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—ovarian cancer	1.47e-06	7.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.46e-06	7.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—ovarian cancer	1.45e-06	6.97e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—ovarian cancer	1.45e-06	6.96e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	1.44e-06	6.94e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—ovarian cancer	1.44e-06	6.94e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.44e-06	6.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—ovarian cancer	1.43e-06	6.9e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—ovarian cancer	1.43e-06	6.88e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—ovarian cancer	1.43e-06	6.88e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—ovarian cancer	1.43e-06	6.87e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.42e-06	6.83e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—ovarian cancer	1.39e-06	6.69e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—ovarian cancer	1.38e-06	6.64e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—ovarian cancer	1.37e-06	6.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—ovarian cancer	1.33e-06	6.41e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—ovarian cancer	1.32e-06	6.35e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.31e-06	6.31e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—ovarian cancer	1.3e-06	6.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—ovarian cancer	1.3e-06	6.27e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—ovarian cancer	1.3e-06	6.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	1.28e-06	6.15e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—ovarian cancer	1.27e-06	6.12e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.24e-06	5.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—ovarian cancer	1.24e-06	5.94e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—ovarian cancer	1.23e-06	5.92e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.21e-06	5.82e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—ovarian cancer	1.18e-06	5.69e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.16e-06	5.57e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—ovarian cancer	1.13e-06	5.46e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—ovarian cancer	1.13e-06	5.44e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—ovarian cancer	1.13e-06	5.44e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—ovarian cancer	1.09e-06	5.26e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—ovarian cancer	1.07e-06	5.14e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.06e-06	5.1e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.05e-06	5.08e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—ovarian cancer	1.05e-06	5.03e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—ovarian cancer	1.04e-06	5.02e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—ovarian cancer	1e-06	4.82e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	9.27e-07	4.46e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—ovarian cancer	9.23e-07	4.44e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	9.18e-07	4.42e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—ovarian cancer	8.66e-07	4.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	8.08e-07	3.89e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	8e-07	3.85e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.54e-07	3.63e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—ovarian cancer	7.5e-07	3.61e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—ovarian cancer	6.98e-07	3.36e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—ovarian cancer	6.53e-07	3.14e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—ovarian cancer	6.16e-07	2.96e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.93e-07	2.37e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—ovarian cancer	4.02e-07	1.94e-06	CbGpPWpGaD
